期刊
CANCER GENE THERAPY
卷 29, 期 3-4, 页码 326-340出版社
SPRINGERNATURE
DOI: 10.1038/s41417-021-00312-w
关键词
-
类别
资金
- Natural Science Foundation Youth Project of Shaanxi Province [2018JQ8014]
- Subject Innovation Team of Shaanxi University of Chinese Medicine [2019-YL06]
LOC554202 is upregulated in HCC patients and can promote HCC progression by competitively binding to miR-485-5p. This suggests that targeting the FOXO3/LOC554202/miR-485-5p/BSG axis may be beneficial for HCC treatment.
Long non-coding RNAs (LncRNAs) have played very important roles in the malignancy behaviors of hepatocellular carcinoma (HCC). LncRNA LOC554202 (LOC554202) was a newly identified tumor-related lncRNA. However, its expression and function in HCC remained unknown. In this study, we firstly reported that LOC554202 expression was distinctly upregulated in HCC specimens and cell lines. Clinical assays indicated that increased LOC554202 expression had a diagnostic value for HCC patients and was positively associated with advanced stages and poor clinical prognosis. Additionally, forkhead box O3(FOXO3) could bind directly to the LOC554202 promoter region and activate its transcription. Functionally, we observed that knockdown of LOC554202 suppressed the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) progress of HCC cells, and promoted apoptosis. Mechanistically, LOC554202 competitively bound to miR-485-5p and prevented the suppressive effects of miR-485-5p on its target gene basigin (BSG), which finally led to HCC metastasis, EMT, and docetaxel chemoresistance. Our data demonstrated that FOXO3-induced LOC554202 contributed to HCC progression by upregulating BSG via competitively binding to miR-485-5p, which suggested that the regulation of the FOXO3/LOC554202/miR-485-5p/BSG axis may have beneficial effects in the treatment of HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据